Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
Tyrosine kinase inhibitors (TKIs) were the first drugs to use an intracellular signaling molecule as a therapeutic target. Unresponsiveness to TKIs limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (HSCT) the only option leading to molecular remission. The aim of...
Gespeichert in:
Veröffentlicht in: | International journal of hematology- oncology and stem cell research 2017-01, Vol.11 (1), p.30-36 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 36 |
---|---|
container_issue | 1 |
container_start_page | 30 |
container_title | International journal of hematology- oncology and stem cell research |
container_volume | 11 |
creator | Carvalho, Franceli Ramos Zuckermann, Joice Paz, Alessandra Fischer, Gustavo Daudt, Liane Esteves Rigoni, Lisandra Della Costa Silla, Lúcia Fogliatto, Laura de Castro, Simone Martins Pilger, Diogo André |
description | Tyrosine kinase inhibitors (TKIs) were the first drugs to use an intracellular signaling molecule as a therapeutic target. Unresponsiveness to TKIs limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (HSCT) the only option leading to molecular remission. The aim of this study is to characterize CML patients unresponsive to first- and/or second-generation TKI therapy who underwent HSCT and to describe the main factors associated with treatment failure.
Twenty one CML patients who underwent allogeneic HSCT and had previously used first- and/or second-generation TKIs from January 2005 to May 2014.
Of the 21 patients, 52.4% were male, with a median age of 49 years (23-65 years) and 85.7% had chronic phase CML at the time of diagnosis; 28.6% showed inadequate treatment adherence to TKI therapy. Thirteen patients were resistant and eight were intolerant to TKIs; additionally, nine did not have T315I mutation. Ten transplantations involved related donors, and more than a half of patients (11) died, three of which due to graft failure. Most patients who survived transplantation were in the chronic phase of disease at the time of HSCT.
The population was composed mainly of young age patients at diagnosis, male, white, and coming from areas in the state of Rio Grande do Sul other than Porto Alegre and metropolitan region. Low adherence to TKI therapy may be related to unresponsiveness to treatment, especially in patients with acquired resistance, or this low adherence, together with the presence of molecular changes, may have led to the need for HSCT. |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5338279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28286612</sourcerecordid><originalsourceid>FETCH-LOGICAL-p181t-41ea8f61c79cd32071c2dd19c611b130daba7af65d82496016172da83562fd7f3</originalsourceid><addsrcrecordid>eNpVkO9KwzAUxYsobsy9guQFCkna9c8XYRR1w4mCG34st83tGmyTkmQb84F8ToNO0U_3XM69Pw7nLBhzSrOQc5qen3REaT4KptbKisZxGtM8oZfBiGc8SxLGx8FH0YKB2qGR7-CkVkQ35NkrVM6Sg3QtKVqjlazJ4xE7LQVZ4e4NewlkowzaQSsr90icJuuj0VYqJA9SgUWyVK2spNPGktdW-3OB5uC5ZN51eosKPXSBPTg9aInOby8Oe1Jg15G1AWWHDpT7SnUVXDTQWZye5iTY3N2ui0W4erpfFvNVOLCMuTBmCFmTsDrNaxH5HljNhWB5nTBWsYgKqCCFJpmJjMe-CpawlAvIolnCG5E20SS4-eYOu6pHUfu0BrpyMLIHcyw1yPK_o2RbbvW-nEVRxtPcA67_An4_fxqPPgFi1YTy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Carvalho, Franceli Ramos ; Zuckermann, Joice ; Paz, Alessandra ; Fischer, Gustavo ; Daudt, Liane Esteves ; Rigoni, Lisandra Della Costa ; Silla, Lúcia ; Fogliatto, Laura ; de Castro, Simone Martins ; Pilger, Diogo André</creator><creatorcontrib>Carvalho, Franceli Ramos ; Zuckermann, Joice ; Paz, Alessandra ; Fischer, Gustavo ; Daudt, Liane Esteves ; Rigoni, Lisandra Della Costa ; Silla, Lúcia ; Fogliatto, Laura ; de Castro, Simone Martins ; Pilger, Diogo André</creatorcontrib><description>Tyrosine kinase inhibitors (TKIs) were the first drugs to use an intracellular signaling molecule as a therapeutic target. Unresponsiveness to TKIs limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (HSCT) the only option leading to molecular remission. The aim of this study is to characterize CML patients unresponsive to first- and/or second-generation TKI therapy who underwent HSCT and to describe the main factors associated with treatment failure.
Twenty one CML patients who underwent allogeneic HSCT and had previously used first- and/or second-generation TKIs from January 2005 to May 2014.
Of the 21 patients, 52.4% were male, with a median age of 49 years (23-65 years) and 85.7% had chronic phase CML at the time of diagnosis; 28.6% showed inadequate treatment adherence to TKI therapy. Thirteen patients were resistant and eight were intolerant to TKIs; additionally, nine did not have T315I mutation. Ten transplantations involved related donors, and more than a half of patients (11) died, three of which due to graft failure. Most patients who survived transplantation were in the chronic phase of disease at the time of HSCT.
The population was composed mainly of young age patients at diagnosis, male, white, and coming from areas in the state of Rio Grande do Sul other than Porto Alegre and metropolitan region. Low adherence to TKI therapy may be related to unresponsiveness to treatment, especially in patients with acquired resistance, or this low adherence, together with the presence of molecular changes, may have led to the need for HSCT.</description><identifier>ISSN: 2008-3009</identifier><identifier>EISSN: 2008-2207</identifier><identifier>PMID: 28286612</identifier><language>eng</language><publisher>Iran: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center</publisher><subject>Original</subject><ispartof>International journal of hematology- oncology and stem cell research, 2017-01, Vol.11 (1), p.30-36</ispartof><rights>Copyright : © International Journal of Hematology-Oncology and Stem Cell Research & Tehran University of Medical Sciences</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338279/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338279/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28286612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carvalho, Franceli Ramos</creatorcontrib><creatorcontrib>Zuckermann, Joice</creatorcontrib><creatorcontrib>Paz, Alessandra</creatorcontrib><creatorcontrib>Fischer, Gustavo</creatorcontrib><creatorcontrib>Daudt, Liane Esteves</creatorcontrib><creatorcontrib>Rigoni, Lisandra Della Costa</creatorcontrib><creatorcontrib>Silla, Lúcia</creatorcontrib><creatorcontrib>Fogliatto, Laura</creatorcontrib><creatorcontrib>de Castro, Simone Martins</creatorcontrib><creatorcontrib>Pilger, Diogo André</creatorcontrib><title>Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation</title><title>International journal of hematology- oncology and stem cell research</title><addtitle>Int J Hematol Oncol Stem Cell Res</addtitle><description>Tyrosine kinase inhibitors (TKIs) were the first drugs to use an intracellular signaling molecule as a therapeutic target. Unresponsiveness to TKIs limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (HSCT) the only option leading to molecular remission. The aim of this study is to characterize CML patients unresponsive to first- and/or second-generation TKI therapy who underwent HSCT and to describe the main factors associated with treatment failure.
Twenty one CML patients who underwent allogeneic HSCT and had previously used first- and/or second-generation TKIs from January 2005 to May 2014.
Of the 21 patients, 52.4% were male, with a median age of 49 years (23-65 years) and 85.7% had chronic phase CML at the time of diagnosis; 28.6% showed inadequate treatment adherence to TKI therapy. Thirteen patients were resistant and eight were intolerant to TKIs; additionally, nine did not have T315I mutation. Ten transplantations involved related donors, and more than a half of patients (11) died, three of which due to graft failure. Most patients who survived transplantation were in the chronic phase of disease at the time of HSCT.
The population was composed mainly of young age patients at diagnosis, male, white, and coming from areas in the state of Rio Grande do Sul other than Porto Alegre and metropolitan region. Low adherence to TKI therapy may be related to unresponsiveness to treatment, especially in patients with acquired resistance, or this low adherence, together with the presence of molecular changes, may have led to the need for HSCT.</description><subject>Original</subject><issn>2008-3009</issn><issn>2008-2207</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVkO9KwzAUxYsobsy9guQFCkna9c8XYRR1w4mCG34st83tGmyTkmQb84F8ToNO0U_3XM69Pw7nLBhzSrOQc5qen3REaT4KptbKisZxGtM8oZfBiGc8SxLGx8FH0YKB2qGR7-CkVkQ35NkrVM6Sg3QtKVqjlazJ4xE7LQVZ4e4NewlkowzaQSsr90icJuuj0VYqJA9SgUWyVK2spNPGktdW-3OB5uC5ZN51eosKPXSBPTg9aInOby8Oe1Jg15G1AWWHDpT7SnUVXDTQWZye5iTY3N2ui0W4erpfFvNVOLCMuTBmCFmTsDrNaxH5HljNhWB5nTBWsYgKqCCFJpmJjMe-CpawlAvIolnCG5E20SS4-eYOu6pHUfu0BrpyMLIHcyw1yPK_o2RbbvW-nEVRxtPcA67_An4_fxqPPgFi1YTy</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Carvalho, Franceli Ramos</creator><creator>Zuckermann, Joice</creator><creator>Paz, Alessandra</creator><creator>Fischer, Gustavo</creator><creator>Daudt, Liane Esteves</creator><creator>Rigoni, Lisandra Della Costa</creator><creator>Silla, Lúcia</creator><creator>Fogliatto, Laura</creator><creator>de Castro, Simone Martins</creator><creator>Pilger, Diogo André</creator><general>Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center</general><scope>NPM</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation</title><author>Carvalho, Franceli Ramos ; Zuckermann, Joice ; Paz, Alessandra ; Fischer, Gustavo ; Daudt, Liane Esteves ; Rigoni, Lisandra Della Costa ; Silla, Lúcia ; Fogliatto, Laura ; de Castro, Simone Martins ; Pilger, Diogo André</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p181t-41ea8f61c79cd32071c2dd19c611b130daba7af65d82496016172da83562fd7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carvalho, Franceli Ramos</creatorcontrib><creatorcontrib>Zuckermann, Joice</creatorcontrib><creatorcontrib>Paz, Alessandra</creatorcontrib><creatorcontrib>Fischer, Gustavo</creatorcontrib><creatorcontrib>Daudt, Liane Esteves</creatorcontrib><creatorcontrib>Rigoni, Lisandra Della Costa</creatorcontrib><creatorcontrib>Silla, Lúcia</creatorcontrib><creatorcontrib>Fogliatto, Laura</creatorcontrib><creatorcontrib>de Castro, Simone Martins</creatorcontrib><creatorcontrib>Pilger, Diogo André</creatorcontrib><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of hematology- oncology and stem cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carvalho, Franceli Ramos</au><au>Zuckermann, Joice</au><au>Paz, Alessandra</au><au>Fischer, Gustavo</au><au>Daudt, Liane Esteves</au><au>Rigoni, Lisandra Della Costa</au><au>Silla, Lúcia</au><au>Fogliatto, Laura</au><au>de Castro, Simone Martins</au><au>Pilger, Diogo André</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation</atitle><jtitle>International journal of hematology- oncology and stem cell research</jtitle><addtitle>Int J Hematol Oncol Stem Cell Res</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>11</volume><issue>1</issue><spage>30</spage><epage>36</epage><pages>30-36</pages><issn>2008-3009</issn><eissn>2008-2207</eissn><abstract>Tyrosine kinase inhibitors (TKIs) were the first drugs to use an intracellular signaling molecule as a therapeutic target. Unresponsiveness to TKIs limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (HSCT) the only option leading to molecular remission. The aim of this study is to characterize CML patients unresponsive to first- and/or second-generation TKI therapy who underwent HSCT and to describe the main factors associated with treatment failure.
Twenty one CML patients who underwent allogeneic HSCT and had previously used first- and/or second-generation TKIs from January 2005 to May 2014.
Of the 21 patients, 52.4% were male, with a median age of 49 years (23-65 years) and 85.7% had chronic phase CML at the time of diagnosis; 28.6% showed inadequate treatment adherence to TKI therapy. Thirteen patients were resistant and eight were intolerant to TKIs; additionally, nine did not have T315I mutation. Ten transplantations involved related donors, and more than a half of patients (11) died, three of which due to graft failure. Most patients who survived transplantation were in the chronic phase of disease at the time of HSCT.
The population was composed mainly of young age patients at diagnosis, male, white, and coming from areas in the state of Rio Grande do Sul other than Porto Alegre and metropolitan region. Low adherence to TKI therapy may be related to unresponsiveness to treatment, especially in patients with acquired resistance, or this low adherence, together with the presence of molecular changes, may have led to the need for HSCT.</abstract><cop>Iran</cop><pub>Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center</pub><pmid>28286612</pmid><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2008-3009 |
ispartof | International journal of hematology- oncology and stem cell research, 2017-01, Vol.11 (1), p.30-36 |
issn | 2008-3009 2008-2207 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5338279 |
source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
subjects | Original |
title | Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A12%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20Patients%20with%20Chronic%20Myeloid%20Leukemia%20Unresponsive%20to%20Tyrosine%20Kinase%20Inhibitors%20Who%20Underwent%20Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplantation&rft.jtitle=International%20journal%20of%20hematology-%20oncology%20and%20stem%20cell%20research&rft.au=Carvalho,%20Franceli%20Ramos&rft.date=2017-01-01&rft.volume=11&rft.issue=1&rft.spage=30&rft.epage=36&rft.pages=30-36&rft.issn=2008-3009&rft.eissn=2008-2207&rft_id=info:doi/&rft_dat=%3Cpubmed%3E28286612%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28286612&rfr_iscdi=true |